Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study

NCT07488572 | Enrolling By Invitation Phase 2 DMC

• 1 other identifier: 2025-FXY-506
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This study is testing a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread to other parts of the body (metastatic clear cell renal cell carcinoma). AK112 is a special kind of drug called a dual-target antibody that works in two ways: it helps the immune system fight cancer and blocks blood vessels that feed the tumor. The goal of this study is to see how well AK112 works as a first-line treatment (before any other treatment) and how safe it is. We will look at how many patients' tumors shrink or stop growing, how long they live without their disease getting worse, and whether they have side effects. This is a Phase II, single-arm, open-label study, meaning all participants will receive AK112, and everyone involved knows what treatment is being given. The study will take place at multiple hospitals across China and will include about 60 patients aged 18 to 75 years who have not received prior systemic treatment for advanced kidney cancer. Participants will receive AK112 through an IV infusion every three weeks until the cancer progresses or side effects become too severe. They will have regular check-ups, including blood tests, imaging scans (like CT or MRI), and physical exams to monitor their health and response to treatment. The study is expected to start in November 2023 and end in June 2027. Participation is voluntary, and all medical care related to the study will be provided at no cost. Participants may also be covered by clinical trial insurance in case of unexpected harm. We hope this study will help find a better treatment option for people with advanced kidney cancer.

Conditions

Renal Cell Carcinoma (RCC); Metastatic Clear Cell Renal Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate (ORR)

  The objective response rate (ORR) is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) according to RECIST v1.1 criteria, assessed by independent radiology review. ORR will be evaluated at baseline and every 6 weeks thereafter until disease progression or withdrawal from the study. The primary endpoint will be analyzed in the intent-to-treat (ITT) population.

  From study start to data cutoff date (approximately 24 months)

Secondary Outcomes (6)

• Disease Control Rate (DCR)

  From study start to data cutoff date (approximately 24 months)

• Overall Survival (OS)

  From first dose of study drug to death from any cause, up to 36 months

• Incidence of Treatment-Emergent Adverse Events (TEAEs)

  During treatment and up to 30 days after last dose

• Changes in Laboratory Parameters

  Baseline, every cycle, and at end of treatment; up to 24 months

• Vital Signs Monitoring

  At screening, baseline, every cycle, and at end of treatment; up to 24 months

Study Arms (1)

Yivoximab Monotherapy Arm

EXPERIMENTAL

This arm includes patients with metastatic clear cell renal cell carcinoma who receive Yivoximab (AK112) as first-line monotherapy. The drug is administered intravenously at a dose of 20 mg/kg every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent. All participants are followed for efficacy and safety outcomes, including objective response rate, progression-free survival, overall survival, and adverse events.

Drug: Yivoximab

Interventions

Yivoximab DRUG

Yivoximab (AK112) is a human IgG1κ dual-target monoclonal antibody that simultaneously binds to PD-1 and VEGF. It is administered intravenously at a dose of 20 mg/kg every 3 weeks as monotherapy. The drug is designed to enhance anti-tumor immune response by blocking immune checkpoint inhibition while inhibiting angiogenesis. This intervention is being evaluated as first-line treatment for metastatic clear cell renal cell carcinoma.

Yivoximab Monotherapy Arm

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 18 and 75 years, inclusive.
• Histologically confirmed diagnosis of clear cell renal cell carcinoma (ccRCC).
• Metastatic disease with at least one measurable lesion according to RECIST v1.1 criteria.
• No prior systemic therapy for advanced or metastatic ccRCC.
• ECOG Performance Status of 0 or 1.
• Expected survival ≥12 weeks.
• Adequate organ function:
• Hemoglobin ≥9 g/dL
• Absolute neutrophil count ≥1.5 × 10⁹/L
• Platelets ≥100 × 10⁹/L
• Total bilirubin ≤1.5 × ULN
• AST/ALT ≤2.5 × ULN (≤5.0 × ULN if liver metastases present)
• Serum creatinine ≤1.5 × ULN or eGFR ≥60 mL/min/1.73m²
• INR ≤1.5 or aPTT within normal limits
• Female patients of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraception during the study and for 12 weeks after last dose.

You may not qualify if:

• \. Non-clear cell histology or mixed histology with non-clear cell component \>25%.
• \. Prior treatment with PD-1/PD-L1 inhibitors, VEGF/VEGFR inhibitors, or other immune checkpoint inhibitors.
• \. Active autoimmune disease requiring systemic immunosuppressive therapy. 4. Uncontrolled hypertension (systolic BP \>150 mmHg or diastolic BP \>100 mmHg despite medication).
• \. Significant cardiovascular disease including unstable angina, myocardial infarction, or congestive heart failure (NYHA Class III-IV) within 6 months.
• \. Symptomatic central nervous system metastases or spinal cord compression. 7. Active infection including HBV, HCV, HIV, or active tuberculosis. 8. Known hypersensitivity to AK112 or its excipients. 9. Pregnancy or breastfeeding. 10. Any condition that may interfere with the interpretation of study results or pose an undue risk to the participant, as determined by the investigator.

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

Location

MeSH Terms

Conditions

Carcinoma, Renal Cell; Clear-cell metastatic renal cell carcinoma

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Masking Details: Not applicable. This is an open-label study with no masking of any role.
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 19, 2026
• First Posted: March 23, 2026
• Study Start: November 1, 2025
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2027
• Last Updated: March 23, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)